(Q33233270)

24 July 2017

1 reference

title

Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities (English)

1 reference

24 July 2017

0 references

4

Alexander M M Eggermont

1 reference

24 July 2017

Dirk J Grünhagen

1

0 references

Timo L M ten Hagen

series ordinal

3

object named as

Timo L M ten Hagen

1 reference

24 July 2017

2

Johannes H W de Wilt

1 reference

24 July 2017

publication date

1 February 2006

1 reference

Nature Clinical Practice Oncology

24 July 2017

published in

1 reference

24 July 2017

volume

3

1 reference

24 July 2017

issue

2

1 reference

24 July 2017

page(s)

94-103

1 reference

Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Is local recurrence of minor importance for metastases in soft tissue sarcoma?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Preoperative chemoradiation treatment strategies for localized sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Chemotherapy of Sarcomas of the Limbs by Regional Perfusion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Regional therapy of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Soft tissue limb sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion with high-dose tumor necrosis factor alpha and melphalan for Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion with tumor necrosis factor‐α and melphalan for patients with unresectable soft tissue sarcoma of the extremities

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

TNF-based isolated limb perfusion in unresectable extremity desmoid tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

TNF dose reduction in isolated limb perfusion.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

TNF is here to stay--revisited

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0426

7 January 2021

Identifiers

DOI

10.1038/NCPONC0426

1 reference

24 July 2017

1 reference